Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

NCT05377996 is registered in ClinicalTrials.gov with Day One Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT05377996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05377996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Lead sponsor
Day One Biopharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 15, 2022
Completion date
December 31, 2027
Enrollment
360 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, breast cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer, triple negative breast cancer